Volume 7, Issue 12

New Clinical Options for Treatment-Experienced Patients with HIV

In this issue:

Treatment-experienced patients with RAMs — resistance-associated mutations — remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patient’s ART history. How will new and in-development agents affect the equation?

Which drug combinations are right? Where does the balance between side effects and adherence lie?

These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this eHIV Review podcast.


Learning objectives:

  • Explain the potential use of the NNRTI doravirine for treatment-experienced individuals, including those with histories of specific NNRTI resistance-associated mutations (RAMs).
  • Describe the use of newer salvage antiretroviral agents as part of combination therapy for heavily treatment-experienced individuals with multiclass drug resistance.


Brian Wood, MD
Brian Wood, MD

Associate Professor of Medicine, Division of Allergy and Infectious Diseases
University of Washington
Seattle, WA

Program Directors:

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: October 11, 2022
Expiration date: October 10, 2024